title: Resveratrol prevents cardiovascular complications in the SHR/STZ rat by reductions in oxidative stress and inflammation.
abstract: The cardioprotective effects of resveratrol are well established in animal models of metabolic disease but are yet to be investigated in a combined model of hypertension and diabetes. This study investigated the ability of resveratrol's antioxidant and anti-inflammatory effects to prevent cardiovascular complications in the spontaneously hypertensive streptozotocin-induced diabetic rat. Diabetes was induced in eight-week-old male spontaneously hypertensive rats via a single intravenous injection of streptozotocin. Following this, resveratrol was administered orally for an eight-week period until the animals were sixteen weeks of age. Upon completion of the treatment regime assessments of oxidative stress, lipid peroxidation, inflammation, and cardiovascular function were made. Resveratrol administration to hypertensive-diabetic animals did not impact upon blood glucose or haemodynamics but significantly reduced oxidative stress, lipid peroxidation, and inflammatory cytokines. Reductions in systemic levels of oxidative stress and inflammation conferred improvements in vascular reactivity and left ventricular pump function and electrophysiology. This study demonstrates that resveratrol administration to hypertensive diabetic animals can elicit cardioprotective properties via antioxidant and anti-inflammatory effects. The observed preservation of cardiovascular function was independent of changes in blood glucose concentration and haemodynamics, suggesting that oxidative stress and inflammation are key components within the pathological cascade associated with hypertension and diabetes.
authors: School of Medical and Applied Sciences, Central Queensland University, Building 81, Bruce Highway, Rockhampton, QLD 4701, Australia.
authors: Rebecca K
authors: RK
authors: Vella
authors: School of Medical and Applied Sciences, Central Queensland University, Building 81, Bruce Highway, Rockhampton, QLD 4701, Australia.
authors: Candice
authors: 0000-0002-7411-0830
authors: C
authors: Pullen
authors: School of Medical and Applied Sciences, Central Queensland University, Building 81, Bruce Highway, Rockhampton, QLD 4701, Australia.
authors: Fiona R
authors: FR
authors: Coulson
authors: School of Medical and Applied Sciences, Central Queensland University, Building 81, Bruce Highway, Rockhampton, QLD 4701, Australia.
authors: Andrew S
authors: AS
authors: Fenning
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D004326:Drinking; D066298:In Vitro Techniques; D007249:Inflammation / Q000150:complications / Q000473:pathology*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008839:Microelectrodes; D009200:Myocardial Contraction / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism; D009599:Nitroprusside / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D018384:Oxidative Stress / Q000187:drug effects; D011918:Rats, Inbred SHR; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013311:Streptozocin; D016276:Ventricular Function / Q000187:drug effects
chemical_list: D013267:Stilbenes; D009599:Nitroprusside; D009569:Nitric Oxide; D013311:Streptozocin; D000109:Acetylcholine; D000077185:Resveratrol; D009638:Norepinephrine